Press Release Tubulis
2022-05-03

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Tubulis Closes €60 Million Series…
read more
Cellaïon Press Release
2022-03-29

Cellaïon announces update to its Board of Directors: Dr. Fouzia LAGHRISSI-THODE joins the biotech as Member of the Board

Cellaïon announces update to its…
read more
Confo Therapeutics Press Release
2022-03-10

Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain

Confo Therapeutics Doses First Subjects…
read more
Immunic Press Release
2022-02-24

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

– Initiated Enrollment in Phase…
read more
Press Release TargED
2022-02-22

TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients

TargED Biopharmaceuticals raises EUR 39…
read more
eTheRNA Press Release
2022-02-03

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

Partnership Press Release eTheRNA Announces…
read more
Epics Therapeutics Press Release
2022-01-13

Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer.

January 12th, 2022 – Epics…
read more
Confo Therapeutics Press Release
2021-12-16

Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform

Confo Therapeutics Expands Patent Estate…
read more
Immunic Press Release
2021-12-14

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

- Unblinded Data Established a…
read more
Immunic Press Release
2021-12-10

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

NEW YORK, Dec. 9, 2021…
read more